Testing effectiveness (Phase 2)Study completedNCT00216697
What this trial is testing
An Extension Study to Provide Bortezomib to Patients With Relapsed or Refractory Multiple Myeloma Who Previously Participated in a Bortezomib Phase I/II Study and Who May Benefit From Re-Treatment With or Continuation of Bortezomib Therapy
Who this might be right for
Multiple Myeloma
Janssen Pharmaceutical K.K. 13